Clinicopathological and prognostic significance of circulating tumor cells in patients with lung cancer: a meta-analysis

Tingjuan Xu1,2, Guodong Shen1,2, Min Cheng1,2, Weiping Xu1,2, Gan Shen1,2 and Shilian Hu1,2

1Gerontology Institute of Anhui Province, Anhui Provincial Hospital Affiliated Anhui Medical University, Hefei 230001, China
2Anhui Provincial Key Laboratory of Tumor Immunotherapy and Nutrition Therapy, Hefei 230001, China

Correspondence to: Shilian Hu, email: hushilian@126.com

Keywords: circulating tumor cells, lung cancer, prognosis, clinicopathological parameters, meta-analysis

Received: November 04, 2016  Accepted: April 25, 2017  Published: July 10, 2017

ABSTRACT

Background: The prognostic significance of circulating tumor cells in patients with lung cancer is controversial. Therefore, we aimed to comprehensively and quantitatively assess the prognostic role of CTCs in patients with lung cancer.

Methods: The relevant literature was searched using PubMed, the Cochrane database and the China National Knowledge Internet database (up to June 2016). Using Review Manager 5.1.2, a meta-analysis was performed using hazard ratio (HR), odds ratio (OR) and 95% confidence interval (CI) as effect values.

Results: Thirty studies comprising 2,060 patients with lung cancer were analyzed. The pooled HR values showed that circulating tumor cells were significantly correlated with overall survival (HR =2.63, 95% CI [2.04, 3.39]) and progression-free survival (HR =3.74, 95% CI [2.49, 5.61]) in these patients. Further subgroup analyses were conducted and categorized by sampling time, detection method, and histological type; these analyses showed the same trend. The pooled OR values showed that circulating tumor cells were associated with non small cell lung cancer stage (OR = 2.11, 95% CI [1.42, 3.14]), small cell lung cancer stage (OR = 10.91, 95% CI [4.10, 29.06]), distant metastasis (OR =7.06, 95%CI [2.82, 17.66]), lymph node metastasis (OR =2.31, 95% CI [1.19,4.46]), and performance status(OR =0.42, 95%CI [0.22, 0.78]).

Conclusion: The detection of circulating tumor cells in the peripheral blood of patients with lung cancer can be indicative of a poor prognosis.

INTRODUCTION

Lung cancer is one of the deadliest diseases in the world. Less than 15% of lung cancer patients survive for more than 5 years after being diagnosed [1]. Due to its aggressive behavior and greater invasive ability than other types of cancer, the predominant cause of treatment failure in patients with lung cancer is believed to be distant metastases, even during early-stage disease. Approximately 25% to 50% of patients with early-stage non small cell lung cancer (NSCLC) show tumor recurrence, even after tumor resection [2, 3]. However, current staging methods are unable to detect such occult metastases prior to the emergence of clinical manifestations [4]. Thus, there is an urgent need for more-sensitive prognostic and predictive markers.

Circulating tumor cells (CTCs) can be found in the peripheral blood of patients with cancer. Many studies have demonstrated the potential usefulness of CTCs in predicting patient prognosis for several cancer types [5–7]. Many studies have also shown associations between CTCs and poor survival in lung cancer [8–11]. However, the prognostic significance of CTCs in lung cancer remains controversial, as other studies have failed to show an association between CTCs and poor prognosis [12]. In addition, assessing the potential of using CTCs as a prognostic marker has been complicated by inter-study differences in aspects such as study population, methodology and sampling time.
Thus, our meta-analysis aimed to examine the association of CTCs with survival and clinicopathological parameters, and to evaluate the prognostic role of CTCs in patients with lung cancer.

RESULTS

Characteristics of the included studies

After initial literature searches, 153 articles were retrieved, and 4 duplicate articles were excluded. After screening the titles and abstracts, 67 studies remained, and their full texts were assessed for eligibility. Of the eligible studies, 37 studies were excluded because they lacked an outcome of interest. Ultimately, 30 studies were selected for analysis; these comprised 24 studies published in English and 6 studies published in Chinese (Figure 1).

The analyzed studies were from the Netherlands, the United Kingdom, America, Spain, Japan, Korea and China, and included a total of 2,060 patients. The median number of patients in each study was 69 (range, 28-208). Of these 30 studies, 2 studies addressed both NSCLC and small cell lung cancer (SCLC); 22 studies addressed NSCLC alone, and 6 addressed SCLC alone. The sampling time was divided into two time points: namely, pre- and post-treatment. Both time points were included in 12 studies [9–11, 13–21], pretreatment alone in 15 studies [8, 12, 22–34] and post-treatment alone in 3 studies [35–37]. Nine studies used the reverse-transcriptase polymerase chain reaction (RT-PCR) method, and 21 studies used other methods. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) could be extracted from 12 studies and 4 studies, respectively. The patient clinical characteristics and the design variables of the studies are summarized in Table 1. The quality of the 30 included studies was evaluated according to the Newcastle-Ottawa scale (NOS) (Table 2). Twenty-five studies were of high quality (NOS score ≥ 5), and 5 studies were of low quality (NOS score < 5).

The prognostic effect (OS and PFS) of CTC detection

The pooled HR values showed a significant correlation between CTCs and OS in patients with lung cancer (HR =2.63, 95% confidence interval (CI) [2.04, 3.39], P<0.00001, I²=19%) (Figure 2). Subsequently, subgroup analyses were conducted after categorization by sampling time, detection method, and histological type to further investigate the prognostic role of CTCs. We found a significant correlation between CTCs and OS in the NSCLC (HR =2.55, 95% CI [1.65, 3.93],...
Table 1: Characteristics and design variables of the including studies

| Author         | Country | No. of patients | Age       | Histological features | Treatment | Sampling volume | Methods      | Markers             | Sampling time | Cutoff of CTC |
|----------------|---------|-----------------|-----------|-----------------------|-----------|-----------------|--------------|---------------------|---------------|---------------|
| Chen TF et al  | China   | 67              | 62(40-75) | ADC 32 SQC 32 Others 3 | chemo. and radio. | 8ml             | RT-PCR       | CK19 mRNA           | pre and post  | NR            |
| Hiltermann TJ et al | Holland | 59              | 64(47-84) | SCLC 59               | chemo. and radio. | 7.5ml           | Cellsearch   | EpCAM, CK8, 18, 19, DAPI | pre and post  | 2 CTCs        |
| Hofman V et al | NR      | 208             | 63(37-84) | ADC 115 SQC 54 Others 39 | surg.     | 10ml            | ISET         | NR                  | pre           | 50            |
| Hou JM et al   | UK      | 97              | 68(28-84) | SCLC 97               | chem.     | 7.5ml           | Cellsearch, ISET | EpCAM, CK8, 18, 19, DAPI | pre and post  | 50 CTCs       |
| Igawa S et al  | Japan   | 30              | 69(51-85) | SCLC 30               | chem.     | 7.5ml           | IF           | GFP                 | pre and post  | 2 CTCs        |
| Krebs MG et al | UK      | 101             | 67(43-84) | ADC 31 SQC 32 Other 38 | chemo. and radio. | 7.5ml           | Cellsearch   | EpCAM, CK8, 18, 19, DAPI | pre and post  | 2 CTCs        |
| Naito T et al  | Japan   | 51              | 67(34-92) | SCLC 51               | chem. or radio.  | 7.5ml           | Cellsearch   | EpCAM, CK8, 18, 19, DAPI | pre           | 8 CTCs        |
| Nieva J et al  | America | 28              | 64(31-82) | ADC 21 SQC 5 Others 2 | chemo. or biotherapy | NR             | IF           | CK 1, 4-8, 10, 13, 18, 19, DAPI | pre          | 1 CTC         |
| Shi WJ et al   | China   | 55              | 59(41-75) | SCLC 55               | chem.     | 10ml            | RT-Q-PCR      | CK19 mRNA            | pre and post  | 3.8           |
| Yamashita J et al | Japan   | 103             | 68(35-83) | ADC 66 SQC 37         | surg.     | NR              | RT-PCR       | CEA mRNA             | pre and post  | NR            |
| Yie SM et al   | China   | 143             | 57(30-84) | ADC 87 SQC 56         | surg. or chem. | 2ml             | RT-PCR       | Survivin mRNA        | pre           | 1.02pg/ml     |
| Yoon SO et al  | Korea   | 79              | 66(42-87) | ADC 45 SQC 27 Others 7 | surg.     | NR              | RT-PCR       | TTF-1, CK19 mRNA     | pre and post  | NR            |
| Juan O et al   | Spain   | 37              | 71(44-85) | ADC 14 SQC 14 Others 9 | chem.     | 7.5ml           | Cellsearch   | EpCAM, CK8, 18, 19, DAPI | pre and post  | 2 CTCs        |
| Sher YP et al  | China   | 54              | 65(28-81) | ADC 35 SQC 14 Others 5 | surg. or chem. | 3-4ml           | RT-PCR       | keratin 19, Ubiquitin thiolesterase C, HSFIB1 | pre          | NR            |
| Bayarri-Lara C et al | Spain   | 56              | 67.4(45-80) | ADC 25 SQC 29 Others 2 | surg.     | 10ml            | IF           | EGFR, CK             | pre and post  | NR            |
| Chen X et al   | China   | 169             | NR        | ADC 112 SQC 51 Others 6 | NR         | 7.5ml           | Cellsearch   | EpCAM, CK8, 18, 19, DAPI | pre           | 1 CTC         |
| Hirose T et al | Japan   | 33              | 64(46-74) | ADC 24 SQC 8 Others 1 | chem.     | 7.5ml           | Cellsearch   | EpCAM, CK8, 18, 19, DAPI | pre           | 1 CTC         |
| Ji JL et al    | China   | 56              | 68(38-80) | NSCLC                 | surg.     | 2ml             | ICC          | EpCAM               | post          | 1 CTC         |
| Lou JT et al   | China   | 33              | 58(33-76) | ADC 16 SQC 11 Others 6 | chem.     | 3ml             | LT-PCR       | CK, FR, DAPI         | pre           | 8.5           |
| Peck K et al   | China   | 86              | 66(26-82) | ADC 47 SQC 17 SCLC 15 Others 7 | surg. or chem. or radio. | 3-5ml           | RT-PCR       | CK19 mRNA             | pre           | NR            |
| Sheu CC et al  | China   | 100             | 64(37-87) | ADC 72 SQC 28         | NR         | 5ml             | RT-PCR       | 17genes              | pre           | NR            |
| Wang B et al   | China   | 42              | 68(37-80) | ADC 25 SQC 17         | surg.     | 10ml            | ICC          | EpCAM               | post          | 1 CTC         |
| Wu C et al     | China   | 47              | NR        | ADC 27 SQC 7 SCLC 13  | chem.     | 7.5ml           | IF           | CK18, 19, DAPI       | pre           | 2 CTCs        |
| Xu YH et al    | China   | 66              | 69(34-80) | ADC 35 SQC 31         | chem.     | 7.5ml           | Cellsearch   | EpCAM, CK8, 18, 19, DAPI | pre and post  | 1 CTC         |

(Continued)
Table 3, the incidence of CTC detection in patients with tumor stage in patients with lung cancer. As shown in the results of the analysis showed that CTCs could be a prognostic indicator of OS both pretreatment (HR =2.73, 95% CI [1.68, 4.43], P<0.0001, I²=24%) and post-treatment (HR =4.27, 95% CI [2.60, 7.02], P<0.0001, I²=27%) or other methods (HR =4.56, 95% CI [2.27, 9.17], P<0.0001, I²=0%) were used.

The pooled HR values revealed a significant correlation between CTCs and PFS in patients with lung cancer (HR =3.74, 95% CI [2.49, 5.61], P<0.00001, I²=0%) (Figure 3). The subgroup analyses showed a significant correlation between CTCs and PFS in the NSCLC (HR =3.91, 95% CI [2.32, 6.60], P<0.00001, I²=0%) and SCLC subgroups (HR =3.49, 95% CI [1.84, 6.63], P=0.0001, I²=0%). In addition, we found that CTCs could be a prognostic indicator of PFS both pretreatment (HR =2.85, 95% CI [2.09, 3.89], P<0.00001, I²=12%) were used.

The pooled odds ratio (OR) values showed that there was a significant correlation between CTCs and tumor stage in patients with lung cancer. As shown in Table 3, the incidence of CTC detection in patients with stage III/IV was higher than that in patients with stage I/II NSCLC (OR = 2.11, 95% CI [1.42, 3.14], P=0.0002, I²= 20%). Similarly, the incidence of CTC detection in extensive SCLC was higher than that in limited SCLC (OR = 10.91, 95% CI [4.10, 29.06], P<0.00001, I²= 4%). However, the subgroup analyses of studies using the RT-PCR method showed no significant correlation between CTCs and tumor stage in either NSCLC patients or SCLC patients.

We found that the presence of CTCs was significantly increased in lung cancer patients with distant metastasis (OR =7.06, 95%CI [2.82, 17.66], P<0.0001, I²= 46%). Further subgroup analyses conducted and categorized by sampling time, detection method, and histological type showed the same trend. The presence of CTCs was also significantly increased in lung cancer patients with lymph node metastasis (OR = 2.31, 95%CI [1.19, 4.46], P=0.01, I²= 19%), but the subgroup analyses showed a significant correlation between CTCs and lymph node metastasis only in the pretreatment subgroup. Moreover, all the studies included in this analysis pertained to NSCLC. We also found that CTCs were associated with performance status (OR = 0.42, 95%CI [0.22, 0.78], P=0.006, I²= 0%). Lower performance scores corresponded to lower CTC incidence. However, the subgroup analyses showed no significant correlation in the post-treatment, PCR or NSCLC subgroups.

Furthermore, pooled analyses of tumor size, performance status, smoking status, and patient age revealed no significant correlation between these clinicopathological parameters and CTCs.

Correlation between CTCs and clinicopathological parameters

The pooled odds ratio (OR) values showed that there was a significant correlation between CTCs and tumor stage in patients with lung cancer. As shown in Table 3, the incidence of CTC detection in patients with stage III/IV was higher than that in patients with stage I/II NSCLC (OR = 2.11, 95% CI [1.42, 3.14], P=0.0002, I²= 20%). Similarly, the incidence of CTC detection in extensive SCLC was higher than that in limited SCLC (OR = 10.91, 95% CI [4.10, 29.06], P<0.00001, I²= 4%). However, the subgroup analyses of studies using the RT-PCR method showed no significant correlation between CTCs and tumor stage in either NSCLC patients or SCLC patients.

We found that the presence of CTCs was significantly increased in lung cancer patients with distant metastasis (OR =7.06, 95%CI [2.82, 17.66], P<0.0001, I²= 46%). Further subgroup analyses conducted and categorized by sampling time, detection method, and histological type showed the same trend. The presence of CTCs was also significantly increased in lung cancer patients with lymph node metastasis (OR = 2.31, 95%CI [1.19, 4.46], P=0.01, I²= 19%), but the subgroup analyses showed a significant correlation between CTCs and lymph node metastasis only in the pretreatment subgroup. Moreover, all the studies included in this analysis pertained to NSCLC. We also found that CTCs were associated with performance status (OR = 0.42, 95%CI [0.22, 0.78], P=0.006, I²= 0%). Lower performance scores corresponded to lower CTC incidence. However, the subgroup analyses showed no significant correlation in the post-treatment, PCR or NSCLC subgroups.

Furthermore, pooled analyses of tumor size, performance status, smoking status, and patient age revealed no significant correlation between these clinicopathological parameters and CTCs.

Test of heterogeneity

Except for the ‘non-PCR on distant metastasis’ subgroup (I²= 70%) and the ‘PCR on lymph node metastasis’ subgroup (I²= 58%), the heterogeneity among all the included studies was not significant. However, when
one study [26] from the ‘non-PCR on distant metastasis’ subgroup was removed, the $I^2$ value was reduced to 0%, while the correlation of CTCs with distant metastasis was unchanged (OR = 14.87, 95% CI [5.00, 44.29], $P$<0.00001). Similarly, when one study [17] from the ‘PCR on lymph node metastasis’ subgroup was removed, the $I^2$ value was reduced to 0%, but the correlation of CTCs with lymph node metastasis was changed (OR = 5.92, 95% CI [1.76, 19.91], $P$ =0.004).

### Sensitivity analyses

We performed sensitivity analyses to test the robustness of the pooled results. The pooled HR was not significantly altered when any individual study was removed. Moreover, the pooled OR was not significantly influenced when any individual study was removed, with the exception of lymph node metastasis. The pooled OR of lymph node metastasis

| Study          | Selection(0-4) | Comparability (0-2) | Outcome(0-3) | Total |
|----------------|----------------|---------------------|--------------|-------|
|                | REC | SNEC | AE | DO | SC | AF | AO | FU | AFU |
| Chen TF        | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 1  | 1    | 7   |
| Hiltermann TJ  | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 1  | 1    | 7   |
| Sher YP        | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 1  | 1    | 7   |
| Hofman V       | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 1  | 0    | 6   |
| Hou JM         | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 1    | 6   |
| Igawa S        | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 1    | 6   |
| Shi WJ         | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 1    | 6   |
| Yamashita Y    | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 1  | 1    | 6   |
| Yie SM         | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 1  | 0    | 6   |
| Yoon SO        | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 1  | 0    | 6   |
| Krebs MG       | 0   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 1    | 5   |
| Naito T        | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Nieva J        | 1   | 1    | 1  | 1  | 0  | 0  | 0  | 0  | 1    | 5   |
| Juan O         | 0   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 1    | 5   |
| Bayarri-Lara C | 1   | 1    | 1  | 1  | 0  | 0  | 0  | 0  | 1    | 5   |
| Chen X         | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Hirose T       | 0   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 1    | 5   |
| Ji JL          | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Peck K         | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Sheu CC        | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Wang B         | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Wu C           | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Feng YQ        | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Lin XM         | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Qian Z         | 1   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 5   |
| Lou JT         | 1   | 1    | 1  | 1  | 0  | 0  | 0  | 0  | 0    | 4   |
| Xu YH          | 0   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 4   |
| Huang TH       | 1   | 1    | 1  | 1  | 0  | 0  | 0  | 0  | 0    | 4   |
| Li J           | 0   | 1    | 1  | 1  | 0  | 0  | 1  | 0  | 0    | 4   |
| Zhao SW        | 1   | 1    | 1  | 1  | 0  | 0  | 0  | 0  | 0    | 4   |
was significantly altered by removal of the study [17] that was the source of heterogeneity.

**Publication bias**

As shown in Figure 4, funnel plots showed no evidence of publication bias. In addition, Egger’s and Begg’s tests were examined to detect publication bias in our article. The results of both Egger’s and Begg’s tests showed no evidence of publication bias ($P > 0.05$).

**DISCUSSION**

Although chemoradiotherapy and surgery have been widely used, lung cancer metastasis and recurrence frequently occur. The poor overall survival of patients and

---

**Figure 2:** Forest plots evaluating the maximally adjusted association between CTC presence and OS. (A) A Forest plot assessing the effect of CTC presence on OS in subgroups divided by sampling time. (B) A Forest plot assessing the effect of CTC presence on OS in subgroups divided by detection method. (C) A Forest plot assessing the effect of CTC presence on OS in subgroups divided by histological type.
the complex heterogeneity of the disease are significant challenges for therapeutic intervention. Therefore, biomarkers that can be used to identify lung cancer recurrence or metastasis are needed to facilitate timely diagnosis and effective treatment strategies for lung cancer patients. CTCs, which are released by primary tumors or metastatic tumors, have been recognized as the cause of tumor metastasis or recurrence [38, 39]. However, the clinicopathological and prognostic significance of CTC detection in patients with lung cancer is not clear. In this meta-analysis, we provide strong evidence that CTCs are significantly associated with poor OS and PFS in lung cancer patients, irrespective of sampling time, detection method, and histological type. All the pooled HRs were above 2.0 in our study. These results demonstrate that a CTC-high status indicates poor prognosis in lung cancer patients; these patients may need more-aggressive treatment that is assessed frequently and closely monitored.

According to the pooled ORs in our meta-analysis, CTCs were associated with tumor stage, lymph node metastasis, distant metastasis, and performance status in patients with lung cancer. The results indicated that CTCs can be predictors of disease progression, and may be used to estimate the degree of malignancy and metastatic ability in lung cancer. However, the analysis of lymph node metastasis showed that the correlation occurred only in the pretreatment subgroup. It is generally believed that lymph node metastasis occurs prior to blood-borne metastasis, but the detection of CTCs in patients with early tumors indicates that blood-borne metastasis can occur before lymph node metastasis. In one study [24], the incidence of CTC detection was higher in patients with lymph node metastasis than in those free of lymph node metastasis. However, in other studies [17, 19, 26, 29], the incidence of CTC detection was not correlated with lymph node metastasis. Thus, the correlation between CTCs and lymph node metastasis may require further investigation.

Figure 3: Forest plots evaluating the maximally adjusted association between CTC presence and PFS. (A) A Forest plot assessing the effect of CTC presence on PFS in subgroups divided by sampling time. (B) A Forest plot assessing the effect of CTC presence on PFS in subgroups divided by detection method. (C) A Forest plot assessing the effect of CTC presence on PFS in subgroups divided by histological type.
Table 3: Detailed results of meta-analyses for clinicopathological parameters

| Clinicopathological parameters | Sample time | Study no. | Patient no. | OR(95% CI), P      | Heterogeneity($I^2$, P) |
|-------------------------------|-------------|-----------|-------------|---------------------|-------------------------|
| **NSCLC Stage III/IV vs. I/II** | overall     | 15        | 1123        | 2.11 [1.42, 3.14], 0.0002 | 20%, 0.23               |
|                               | pre         | 12        | 990         | 1.77 [1.17, 2.68], 0.007 | 16%, 0.29               |
|                               | post        | 5         | 248         | 3.72 [1.79, 7.72], 0.0004 | 0%, 0.85                |
|                               | PCR         | 7         | 464         | 1.25 [0.71, 2.19], 0.44 | 7%, 0.37                |
|                               | non-PCR     | 8         | 659         | 2.71 [1.78, 4.13], <0.00001 | 0%, 0.50               |
| **SCLC Extensive vs. Limited** | overall     | 4         | 202         | 10.91 [4.10, 29.06], <0.00001 | 4%, 0.37               |
|                               | pre         | 4         | 202         | 10.91 [4.10, 29.06], <0.00001 | 4%, 0.37               |
|                               | post        | 1         | 55          | 5.75 [1.58, 20.99], 0.008 |                         |
|                               | PCR         | 2         | 70          | 6.30 [0.60, 65.68], 0.12 | 49%, 0.16               |
|                               | non-PCR     | 2         | 132         | 13.87 [4.30, 44.77], <0.00001 | 0%, 0.39               |
| **Distant metastasis (+) vs. (-)** | overall     | 5         | 522         | 7.06 [2.82, 17.66], <0.00001 | 46%, 0.11               |
|                               | pre         | 5         | 522         | 7.06 [2.82, 17.66], <0.00001 | 46%, 0.11               |
|                               | post        | 1         | 55          | 5.75 [1.58, 20.99], 0.008 |                         |
|                               | PCR         | 2         | 155         | 8.58 [2.07, 35.56], 0.003 | 0%, 0.77                |
|                               | non-PCR     | 4         | 367         | 7.13 [1.80, 28.21], 0.005 | 70%, 0.03               |
| **NSCLC**                     | overall     | 3         | 370         | 5.44 [1.40, 21.15], 0.01 | 45%, 0.16               |
| **SCLC**                      | overall     | 2         | 152         | 11.41 [4.15, 31.39], <0.00001 | 0%, 0.54               |
| **Lymph node metastasis (+) vs. (-)** | overall     | 5         | 420         | 2.31 [1.19, 4.46], 0.01 | 19%, 0.29               |
|                               | pre         | 5         | 420         | 2.31 [1.19, 4.46], 0.01 | 19%, 0.29               |
|                               | post        | 2         | 104         | 1.60 [0.57, 4.46], 0.37 | 20%, 0.26               |
|                               | PCR         | 3         | 239         | 2.98 [0.72, 12.29], 0.13 | 58%, 0.09               |
|                               | non-PCR     | 2         | 181         | 2.17 [0.97, 4.88], 0.06 | 0%, 0.60                |
| **NSCLC**                     | overall     | 5         | 420         | 2.31 [1.19, 4.46], 0.01 | 19%, 0.29               |
| **SCLC**                      | overall     | 0         | 0           |                             |                         |
| **Performance status 0-1 vs. 2** | overall     | 4         | 286         | 0.42 [0.22, 0.78], 0.006 | 0%, 0.48                |
|                               | pre         | 4         | 286         | 0.42 [0.22, 0.78], 0.006 | 0%, 0.48                |
|                               | post        | 1         | 55          | 0.85 [0.25, 2.83], 0.79 |                         |
|                               | PCR         | 1         | 55          | 0.69 [0.16, 2.96], 0.62 |                         |
|                               | non-PCR     | 3         | 231         | 0.37 [0.19, 0.74], 0.005 | 0%, 0.39                |
| **NSCLC**                     | overall     | 2         | 134         | 0.59 [0.13, 2.80], 0.51 | 31%, 0.23               |

(Continued)
We analyzed studies reporting the detection of CTCs in peripheral blood before and after treatment. The results from these two sampling time were consistent, except for the correlation of CTCs with lymph node metastasis and performance status. Therefore, CTC detection may offer doctors a simpler, less-invasive method that can be used at an earlier stage of disease (relative to other methods) to estimate disease progression and predict the prognosis of patients before treatment.
In recent years, various new CTC assay methodologies have been developed, including RT-PCR, immunocytochemistry, and the CellSearch System, for example. Each method has its advantages and disadvantages. We obtained different results for the PCR and non-PCR subgroups in analyses of tumor stage, lymph node metastasis, and performance status. CTCs were not associated with these clinicopathological parameters in the PCR subgroup. It thus seems that non-PCR-based methods are best for CTC detection in this context. Several studies have been performed to compare CTC detection methods, but no conclusive results have been obtained as of yet [40]. Therefore, further studies within the same lung cancer patient populations are needed to provide comparative data on the clinical significance of CTCs detected by different methods.

We found significant heterogeneity in the non-PCR subgroup on distant metastasis and in the PCR subgroup on lymph node metastasis. In these two subgroups, CTCs were detected before treatment using the same detection methods. However, the optimal cut-off values for CTC detection were obviously different for the two subgroups. In addition, the markers of CTC detection were not uniform in the PCR-subgroup studies that investigated the association between CTCs and lymph node metastasis. We propose that these two factors might be the principal causes of heterogeneity.

This study has some notable limitations. First, our meta-analysis was limited to the published scientific literature, and univariate data were also included in the present meta-analysis because multivariate survival analysis data were not available. Second, the CTC detection assays varied in our study, and included different endpoints, cut-off values, and experimental designs. Moreover, we excluded some papers that did not calculate OS and PFS, which may have influenced the results to some degree [18, 25, 41].

In conclusion, this meta-analysis indicates that the detection of CTCs in peripheral blood may be an indicator of patient prognosis, and provides evidence that CTC detection can be used to estimate the degree of malignancy and metastatic ability in patients with lung cancer. In the future, high-quality, well-designed and large-scale multicenter studies are needed to further substantiate these findings.

METHODS

Literature search

PubMed, the Cochrane database and the China National Knowledge Internet database were searched for studies pertaining to the clinicopathological and prognostic relationship between CTCs and lung cancer without
language, publication or time restrictions (up to June 2016). The main search terms were “lung or pulmonary or pulmonic or pneumatic” and “cancer or tumor or tumour or carcinoma or neoplasm(s)” and “CTC(s) or circulating tumor cell(s) or neoplastic cell(s) or circulating cancer cell(s) or circulating epithelial cell(s) or micrometastasis”. Furthermore, relevant articles were identified from references cited in the retrieved articles and in review articles by manual searching.

Selection criteria

Eligible studies were included if they met the following criteria: (i) CTCs were detected in lung cancer patients; (ii) samples were collected from peripheral blood; and (iii) at least one of the outcome measures of interest was reported in the study or calculated from published data. When several studies were reported from the same authors or organizations, the meta-analysis included the most recent study (or the highest-quality study if the most recent study did not fit the inclusion criteria).

Studies were excluded if they met any of the following criteria: (i) the number of patients with lung cancer was fewer than 20; (ii) repeated studies were based on the same database or patients; or (iii) they provided insufficient data.

Data extraction and assessment of study quality

Two independent reviewers evaluated each study and extracted data independently, and any disagreements were resolved via discussion. We performed two types of analysis. The first type of analysis determined whether CTC status was associated with OS or PFS. The second type of analysis determined whether CTC status was correlated with clinicopathological parameters, which included tumor size, lymph node metastasis, distant metastasis, NSCLC stage (III/IV vs. I/II), SCLC stage (extensive disease vs. limited disease), gender, age, smoking and performance status. Data for multivariate survival analyses reported in the included articles were included in this meta-analysis. If these data were not available, then univariate analytical data were included. The quality of studies was evaluated according to the NOS [42], and studies with a NOS score ≥ 5 were considered to be of high quality.

Statistical analysis

Statistical analysis was performed using Review Manager 5.1.2 software. The estimated HR was used to evaluate the prognostic effect (OS and PFS), and the estimated OR was used to summarize the association between CTC detection and the clinicopathological characteristics of lung cancer. If the HR and its variance were not reported directly in the original study, then these values were calculated from the available reported data using software designed by Tierney et al. [43]. All statistical values were combined with a 95% CI, and the P-value threshold was set at 0.05. The random-effects mode was used to perform the analysis, as this model produced more conservative results than did the fixed-effects model, and it was a better fit for the multicenter clinical studies owing to the existence of heterogeneity [44]. Heterogeneity was calculated using a Q test, and the I^2 value represented the degree of heterogeneity. Publication bias was tested using a funnel plot, and by Egger’s and Begg’s tests, in Stata 12.0 software. The overall analysis was completed by evaluating all the relevant studies according to different clinicopathological parameters and prognostic outcomes. Further subgroup analyses were conducted and categorized by sampling time (pretreatment and post-treatment), detection method (PCR and non-PCR), and histological type (NSCLC and SCLC). Sensitivity analyses were performed by excluding one study at a time to evaluate the influence of single studies on summary effect values.

Abbreviations

CI, confidence intervals
CTCs, circulating tumor cells
HR, hazard ratio
NOS, Newcastle-Ottawa scale
NSCLC, non small cell lung cancer
OR, odds ratio
OS, overall survival
PFS, progression-free survival
RT-PCR, reverse-transcriptase polymerase chain reaction
SCLC, small cell lung cancer

ACKNOWLEDGMENTS

This work was supported by the Anhui Provincial Project of the Key Laboratory of Tumor Immunotherapy and Nutrition Therapy (1606c08236) and National Natural Science Foundation of China (81471552). We are grateful for this funding support.

CONFLICTS OF INTEREST

There are no potential conflicts of interest to disclose.

REFERENCES

1. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, EUROCare Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol. 2007; 8: 773-783. doi: 10.1016/S1470-2045(07)70245-0.
2. Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, Zureik M. 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol. 2006; 7: 829-836. doi: 10.1016/S1470-2198(06)70868-3.

3. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol. 2000; 18: 106-115.

4. Furák J, Troján I, Szőke T, Ágocs L, Cseké Á, Kas J, Svastics E, Eller J, Tiszlavicz L. Lung cancer and its observable brain metastasis: survival rate and staging problems. Ann Thorac Surg. 2005; 79: 241-247. doi: 10.1016/j.athoracsur.2004.06.051.

5. Bizard FC, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Cottu P, Beuzeboc P, Rolland E, Mathiot C, Pierga JY. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res. 2012; 14: R29. doi: 10.1186/bcr3114.

6. Romiti A, Raffa S, Di Rocco R, Roberto M, Milano A, Zullo A, Leone L, Ranieri D, Mazzetta F, Medda E, Sarcina I, Baruca V, D’Antonio C, et al. Circulating tumor cells count predicts survival in colorectal cancer patients. J Gastrointestin Liver Dis. 2014; 23: 279-284. doi: 10.15403/jgild.2014.1121.233.arom1.

7. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tisdale FF, Trestappen LW, Pienta KJ, Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14: 6302-6309. doi: 10.1158/1078-0432.CCR-08-0872.

8. Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, Flejou JF, Lantuejoul S, Piaton E, Mourad N, Butori C, Selva E, Poudenx M, Sibon S, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res. 2011; 17: 827-835. doi: 10.1158/1078-0432.CCR-10-0445.

9. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraleschi R, Hughes A, Clack G, Ransom M, Dive C, Blackhall FH. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011; 29: 1556-1563. doi: 10.1200/JCO.2010.28.7045.

10. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012; 30: 525-532. doi: 10.1200/JCO.2010.33.3716.

11. Shi WL, Li J, Du YJ, Zhu WF, Wu Y, Hu YM, Chen YC. CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients. Med Oncol. 2013; 30: 755. doi: 10.1007/s12032-013-0755-9.

12. Hirose T, Murata Y, Oki Y, Sugiyama T, Kusumoto S, Ishida H, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ohnishi T, Ohmori T. Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncol Res. 2012; 20: 131-137. doi: 10.3727/096504012x13473665462583.

13. Chen TF, Jiang GL, Fu XL, Wang LJ, Qian H, Wu KL, Zhao S. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer. 2007; 56: 105-114. doi: 10.1016/j.lungcan.2006.11.006.

14. Hiltermann TJ, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJ, Schouwink JH, Wijnands WJ, Kerner GS, Kruyt FA, Tissing H, Tibbe AG, Terstappen LW, Groen HJ. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol. 2012; 23: 2937-2942. doi: 10.1093/annonc/mds138.

15. Igawa S, Gohda K, Fukui T, Ryuge S, Otani S, Masago A, Sato J, Murakami K, Maki S, Katono K, Takakura A, Sasaki J, Masuda N, et al. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett. 2014; 7: 1469-1473. doi: 10.3892/ol.2014.1940.

16. Yamashita J, Matsuo A, Kurasu Y, Saishoji T, Hayashi N, Ogawa M. Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinomaembryonic antigen messenger RNA is an independent predictor of survival in non–small cell lung cancer: a prospective study. J Thorac Cardiovasc Surg. 2002; 124: 299-305. doi: 10.1067/mct.2002.124370.

17. Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH, Kim CW. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer. 2011; 71: 209-216. doi: 10.1016/j.lungcan.2010.04.017.

18. Juan O, Vidal J, Gisbert R, Munoz J, Macia S, Gomez-Codina J. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine. Clin Transl Oncol. 2014; 16: 637-643. doi: 10.1007/s12094-013-1128-8.

19. Bayarri-Lara C, Ortega FG, Cueto Ladrón de Guevara A, Puche JL, Ruiz Zafra J, de Miguel-Perez D, Ramos AS, Giraldo-Ospina CF, Navajas Gomez JA, Delgado-Rodriguez M, Lorente JA, Serrano MJ. Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection. PLoS One. 2016; 11: e0148659. doi: 10.1371/journal.pone.0148659.

20. Xu YH, Zhou J, Pan XF. Detecting circulating tumor cells in patients with advanced non-small cell lung cancer. Genet Mol Res. 2015; 14: 10352-10358. doi: 10.4238/2015.1121.233.arom1.
22. Naito T, Tanaka F, Ono A, Yoneda K, Takahashi T, Murakami H, Nakamura Y, Tsuya A, Kenmotsu H, Shukuya T, Kaira K, Koh Y, Endo M, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol. 2012; 7: 512-519. doi: 10.1097/JTO.0b013e31823f125d.

23. Nieva J, Wendel M, Luttgarten MS, Marrinucho D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol. 2012; 9: 016004. doi: 10.1088/1478-3975/9/1/016004.

24. Yie SM, Lou B, Ye SR, He X, Cao M, Xie K, Ye NY, Lin R, Wu SM, Xiao HB, Gao E. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer. 2009; 63: 284-290. doi: 10.1016/j.lungcan.2008.05.024.

25. Sher YP, Shih JY, Yang PC, Roffler SR, Chu YW, Wu CW, Yu CL, Peck K. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin Cancer Res. 2005; 11: 173-179.

26. Chen X, Wang X, He H, Liu Z, Hu JF, Li W. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS One. 2015; 10: e0126276. doi: 10.1371/journal.pone.0126276.

27. Lou JL, Ben S, Yang G, Liang X, Wang X, Ni S, Han B. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One. 2013; 8: e80458. doi: 10.1371/journal.pone.0080458.g001.

28. Peck K, Sher YP, Shih JY, Roffler SR, Wu CW, Yang PC. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res. 1998; 58: 2761-2765.

29. Sheu CC, Yu YP, Tsai JR, Chang MY, Lin SR, Hwang JJ, Chong IW. Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer. Int J Cancer. 2006; 119: 1419-1426. doi: 10.1002/ijc.21999.

30. Wu C, Hao H, Li L, Zhou X, Guo Z, Zhang L, Zhang X, Zhong W, Guo H, Bremner RM, Lin P. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol. 2009; 4: 30-36. doi: 10.1097/JTO.0b013e3181914125.

31. Feng YQ, Hu CH, Yu J. Clinical value of circulating tumor cell count in non-small cell lung cancer. J Clin Res. 2012; 29: 632-635.

32. Huang TH, Wang Z, Li Q, Li FR, Qi H, Zhou HX. Clinical significance of enrichment and detection of circulating tumor cells in NSCLC patients with immunomagnetic beads. Chin J Oncol. 2007; 29: 676-680.

33. Lin XM, Chen DZ, Jiang CB, Sun CC, He ZF, Zhang X. Detection of circulating cancer cells and vascular endothelial growth factor in lung cancer patients. J Wenzhou Med Coll. 2010; 40: 405-407.

34. Qian Z, Gu ML, Fang CP, Shi L, Li H, Chen Y, Ren CL, Qin Q, Deng AM. The expression and clinical significance of circulating tumor cells in small-cell lung cancer. Chin J Lab Med. 2014; 37: 371-373.

35. Ji JL, Jiang YZ, Tang QQ, He XD, Shen ZJ, Zhang BY. Detection of circulating tumor cells using a novel immunomagnetic bead method in lung cancer patients. J Clin Lab Anal. 2016; 30: 656-662. doi: 10.1002/jcla.21918.

36. Wang B, Wang B, Zhang D, Guo H, Zhang L, Zhou W. Clinical test on circulating tumor cells in peripheral blood of lung cancer patients, based on novel immunomagnetic beads. Artif Cells Nanomed Biotechnol. 2016; 44: 892-897. doi: 10.3109/21691401.2014.998827.

37. Zhao SW, Chu HL, Li YY, Chen W, Bi JW. Significance of detecting circulating tumor cells of postoperative patients with non-small cell lung cancer. J Pract Med. 2015; 32: 146-147. doi: 10.14172/j.cnki.issn1671-4008.2015.02.019.

38. Klein CA. Cancer. The metastasis cascade. Science. 2008; 321: 1785-1787. doi: 10.1126/science.1164853.

39. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331: 1559-1564. doi: 10.1126/science.1203543.

40. Alumni-Fabbioni M, Sandri MT. Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods. 2010; 50: 289-297. doi: 10.1016/j.ymeth.2010.01.027.

41. Liu L, Liao GQ, He P, Zhu H, Liu PH, Qu YM, Song XM, Xu QW, Gao Q, Zhang Y, Chen WF, Yin YH. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun. 2008; 372: 756-760. doi: 10.1016/j.bbrc.2008.05.101.

42. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603-605. doi: 10.1007/s10654-010-9491-z.

43. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. doi: 10.1186/1745-6215-8-16.

44. Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009; 62: 97-128. doi: 10.1348/000711007X255327.